Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its […]
read moreData confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its […]
read moreWALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating […]
read moreWALTHAM, Mass., Sept. 25, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and […]
read moreWALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating […]
read moreWALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating […]
read moreWALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating […]
read moreWALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases […]
read moreWALTHAM, MA., August 20, 2018 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and […]
read moreWALTHAM, Mass., August 07, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies […]
read moreWALTHAM, MA., August 3, 2018 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies […]
read more